 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jun 30, 2016 |
| Title |
Pathologic Immune Pathways in Psoriasis are Rapidly Attenuated by Tofacitinib Treatment: A Randomized Phase 2 Study in Patients with Moderate to Severe Psoriasis |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. We sought to elucidate the molecular mechanisms underlying the clinical efficacy of tofacitinib in patients with psoriasis. Twelve patients with plaque psoriasis were randomized (3:1) to receive 10 mg of tofacitinib or placebo twice daily for 12 weeks. Biopsy specimens were taken from nonlesional (baseline) and lesional (baseline, days 1 and 3, and weeks 1, 2, 4, and 12) skin. Biopsy specimens were examined for psoriatic epidermal features (thickness, Ki67+ keratinocytes and keratin 16 [KRT16] mRNA expression, and phosphorylated signal transducer and activator of transcription [pSTAT]+ nuclei) and T-cell and dendritic cell (DC) subsets by using immunohistochemistry, and mRNA transcripts were quantified by using a microarray. In lesional skin keratinocyte pSTAT1 and pSTAT3 staining was increased at baseline but reduced after 1 day of tofacitinib (baseline, median of 1290 pSTAT1+ cells/?m2; day 1, median of 332 pSTAT1+ cells/?m2; and nonlesional, median of 155 pSTAT1+ cells/?m2). Epidermal thickness and KRT16 mRNA expression were significantly and progressively reduced after days 1 and 3 of tofacitinib administration, respectively (eg, KRT16 decreased 2.74-fold, day 3 vs baseline, P = .016). Decreases in DC and T-cell numbers were observed after weeks 1 and 2, respectively. At week 4, significant decreases in IL-23/TH17 pathways were observed that persisted through week 12. Improvements in clinical and histologic features were strongly associated with changes in expression of psoriasis-related genes and reduction in IL-17 gene expression. Tofacitinib has a multitiered response in patients with psoriasis: (1) rapid attenuation of keratinocyte Janus kinase/STAT signaling; (2) removal of keratinocyte-induced cytokine signaling, leading to reductions in pathologic DC and T-cell numbers to nonlesional levels; and (3) inhibition of the IL-23/TH17 pathway.
|
| |
|
| Overall design |
Twelve patients with plaque psoriasis were randomized (3:1) to receive tofacitinib 10 mg or placebo twice daily for 12 weeks. Biopsies were taken from lesional and non-lesional skin at baseline, and from lesional skin on Day 1, Day 3, and Weeks 1, 2, 4 and 12. Biopsies were examined for psoriatic epidermal features (thickness; Ki67+ keratinocytes, keratin 16 [KRT16] mRNA expression; phosphoSTAT [pSTAT] + nuclei) and T-cell and dendritic cell (DC) subsets using immunohistochemistry. mRNA transcripts were quantified by microarray.
|
| |
|
| Contributor(s) |
Suarez-Farinas M, Krueger J, Whitley M |
| Citation(s) |
27059729, 27667537 |
| Submission date |
Jun 17, 2015 |
| Last update date |
Mar 25, 2019 |
| Contact name |
Mayte Suarez-Farinas |
| E-mail(s) |
mayte.suarezfarinas@mssm.edu
|
| Organization name |
Mount SinaiSchool of Medicine
|
| Street address |
1425 Madison Ave, L2-70C, Box 1077,
|
| City |
New York |
| State/province |
NY |
| ZIP/Postal code |
10075 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (95)
|
| GSM1714118 |
10011001:Placebo,LS,Day 3 |
| GSM1714119 |
10011001:Placebo,LS,Week 1 |
| GSM1714120 |
10011001:Placebo,LS,Week 2 |
| GSM1714121 |
10011001:Placebo,LS,Week 4 |
| GSM1714122 |
10011001:Placebo,LS,Week 12 |
| GSM1714123 |
10011003:Tofacitinib,NL,Day 0 |
| GSM1714124 |
10011003:Tofacitinib,LS,Day 0 |
| GSM1714125 |
10011003:Tofacitinib,LS,Day 1 |
| GSM1714126 |
10011003:Tofacitinib,LS,Day 3 |
| GSM1714127 |
10011003:Tofacitinib,LS,Week 1 |
| GSM1714128 |
10011003:Tofacitinib,LS,Week 2 |
| GSM1714129 |
10011003:Tofacitinib,LS,Week 4 |
| GSM1714130 |
10011003:Tofacitinib,LS,Week 12 |
| GSM1714131 |
10011004:Placebo,NL,Day 0 |
| GSM1714132 |
10011004:Placebo,LS,Day 0 |
| GSM1714133 |
10011004:Placebo,LS,Day 1 |
| GSM1714134 |
10011004:Placebo,LS,Day 3 |
| GSM1714135 |
10011004:Placebo,LS,Week 1 |
| GSM1714136 |
10011004:Placebo,LS,Week 2 |
| GSM1714137 |
10011004:Placebo,LS,Week 4 |
| GSM1714138 |
10011004:Placebo,LS,Week 12 |
| GSM1714139 |
10011005:Tofacitinib,NL,Day 0 |
| GSM1714140 |
10011005:Tofacitinib,LS,Day 0 |
| GSM1714141 |
10011005:Tofacitinib,LS,Day 1 |
| GSM1714142 |
10011005:Tofacitinib,LS,Day 3 |
| GSM1714143 |
10011005:Tofacitinib,LS,Week 1 |
| GSM1714144 |
10011005:Tofacitinib,LS,Week 2 |
| GSM1714145 |
10011005:Tofacitinib,LS,Week 4 |
| GSM1714146 |
10011005:Tofacitinib,LS,Week 12 |
| GSM1714147 |
10021001:Tofacitinib,NL,Day 0 |
| GSM1714148 |
10021001:Tofacitinib,LS,Day 0 |
| GSM1714149 |
10021001:Tofacitinib,LS,Day 1 |
| GSM1714150 |
10021001:Tofacitinib,LS,Day 3 |
| GSM1714151 |
10021001:Tofacitinib,LS,Week 1 |
| GSM1714152 |
10021001:Tofacitinib,LS,Week 2 |
| GSM1714153 |
10021001:Tofacitinib,LS,Week 4 |
| GSM1714154 |
10021002:Tofacitinib,NL,Day 0 |
| GSM1714155 |
10021002:Tofacitinib,LS,Day 0 |
| GSM1714156 |
10021002:Tofacitinib,LS,Day 1 |
| GSM1714157 |
10021002:Tofacitinib,LS,Day 3 |
| GSM1714158 |
10021002:Tofacitinib,LS,Week 1 |
| GSM1714159 |
10021002:Tofacitinib,LS,Week 2 |
| GSM1714160 |
10021002:Tofacitinib,LS,Week 4 |
| GSM1714161 |
10021002:Tofacitinib,LS,Week 12 |
| GSM1714162 |
10021004:Tofacitinib,NL,Day 0 |
| GSM1714163 |
10021004:Tofacitinib,LS,Day 0 |
| GSM1714164 |
10021004:Tofacitinib,LS,Day 1 |
| GSM1714165 |
10021004:Tofacitinib,LS,Day 3 |
| GSM1714166 |
10021004:Tofacitinib,LS,Week 1 |
| GSM1714167 |
10021004:Tofacitinib,LS,Week 2 |
| GSM1714168 |
10021004:Tofacitinib,LS,Week 4 |
| GSM1714169 |
10021004:Tofacitinib,LS,Week 12 |
| GSM1714170 |
10031001:Tofacitinib,NL,Day 0 |
| GSM1714171 |
10031001:Tofacitinib,LS,Day 0 |
| GSM1714172 |
10031001:Tofacitinib,LS,Day 1 |
| GSM1714173 |
10031001:Tofacitinib,LS,Day 3 |
| GSM1714174 |
10031001:Tofacitinib,LS,Week 1 |
| GSM1714175 |
10031001:Tofacitinib,LS,Week 2 |
| GSM1714176 |
10031001:Tofacitinib,LS,Week 4 |
| GSM1714177 |
10031001:Tofacitinib,LS,Week 12 |
| GSM1714178 |
10031002:Tofacitinib,NL,Day 0 |
| GSM1714179 |
10031002:Tofacitinib,LS,Day 0 |
| GSM1714180 |
10031002:Tofacitinib,LS,Day 1 |
| GSM1714181 |
10031002:Tofacitinib,LS,Day 3 |
| GSM1714182 |
10031002:Tofacitinib,LS,Week 1 |
| GSM1714183 |
10031002:Tofacitinib,LS,Week 2 |
| GSM1714184 |
10031002:Tofacitinib,LS,Week 4 |
| GSM1714185 |
10031002:Tofacitinib,LS,Week 12 |
| GSM1714186 |
10081001:Placebo,NL,Day 0 |
| GSM1714187 |
10081001:Placebo,LS,Day 0 |
| GSM1714188 |
10081001:Placebo,LS,Day 1 |
| GSM1714189 |
10081001:Placebo,LS,Day 3 |
| GSM1714190 |
10081001:Placebo,LS,Week 1 |
| GSM1714191 |
10081001:Placebo,LS,Week 2 |
| GSM1714192 |
10081001:Placebo,LS,Week 4 |
| GSM1714193 |
10081001:Placebo,LS,Week 12 |
| GSM1714194 |
10081002:Tofacitinib,NL,Day 0 |
| GSM1714195 |
10081002:Tofacitinib,LS,Day 0 |
| GSM1714196 |
10081002:Tofacitinib,LS,Day 1 |
| GSM1714197 |
10081002:Tofacitinib,LS,Day 3 |
| GSM1714198 |
10081002:Tofacitinib,LS,Week 1 |
| GSM1714199 |
10081002:Tofacitinib,LS,Week 2 |
| GSM1714200 |
10081002:Tofacitinib,LS,Week 4 |
| GSM1714201 |
10081002:Tofacitinib,LS,Week 12 |
| GSM1714202 |
10081003:Tofacitinib,NL,Day 0 |
| GSM1714203 |
10081003:Tofacitinib,LS,Day 0 |
| GSM1714204 |
10081003:Tofacitinib,LS,Day 1 |
| GSM1714205 |
10081003:Tofacitinib,LS,Day 3 |
| GSM1714206 |
10081003:Tofacitinib,LS,Week 1 |
| GSM1714207 |
10081003:Tofacitinib,LS,Week 2 |
| GSM1714208 |
10081003:Tofacitinib,LS,Week 4 |
| GSM1714209 |
10081003:Tofacitinib,LS,Week 12 |
|
| Relations |
| BioProject |
PRJNA287287 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE69967_RAW.tar |
429.4 Mb |
(http)(custom) |
TAR (of CEL) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...